KR20100099115A - 조합된 sert, 5-ht3 및 5-ht1a 활성을 가진 화합물의 치료 용도 - Google Patents
조합된 sert, 5-ht3 및 5-ht1a 활성을 가진 화합물의 치료 용도 Download PDFInfo
- Publication number
- KR20100099115A KR20100099115A KR1020107010492A KR20107010492A KR20100099115A KR 20100099115 A KR20100099115 A KR 20100099115A KR 1020107010492 A KR1020107010492 A KR 1020107010492A KR 20107010492 A KR20107010492 A KR 20107010492A KR 20100099115 A KR20100099115 A KR 20100099115A
- Authority
- KR
- South Korea
- Prior art keywords
- disorders
- depression
- disease
- compound
- anxiety
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
도 2: 히드로브로마이드 염의 알파 형태의 XRPD
도 3: 히드로브로마이드 염의 베타 형태의 XRPD
도 4: 히드로브로마이드 염의 감마 형태의 XRPD
도 5: 히드로브로마이드 염의 반수화물의 XRPD
도 6: 플라시보, 5 mg 및 10 mg 화합물 I (HBr 염) 에 대한 HAM-D 등급평가 항목 4 (불면증 조기) 에서의 6 주에 걸친 변화. 각 군 당 약 100 명의 환자가 있다.
도 7: 플라시보, 5 mg 및 10 mg 화합물 I (HBr 염) 에 대한 HAM-D 등급평가 항목 5 (불면증 중기) 에서의 6 주간의 변화. 각 군 당 약 100 명의 환자가 있다.
도 8: 플라시보, 5 mg 및 10 mg 화합물 I (HBr 염) 에 대한 HAM-D 등급평가 항목 6 (불면증 후기) 에서의 6 주간의 변화. 각 군 당 약 100 명의 환자가 있다.
도 9: 피내 포르말린 시험에서의 화합물 I 의 효과. X-축은 투여된 화합물을 양을 나타내고; Y-축은 발바닥을 핥는데 걸린 시간 (초) 를 나타냄.
도 9a: 0 내지 5 분의 기간 동안의 응답성; 도 9b: 20 내지 30 분의 기간 동안의 응답성.
도 10a: 1-[2-(2,4-디메틸페닐술파닐)페닐]피페라진 HBr 염의 투여시 자유롭게 움직이는 래트에서의 전두엽 피질에서의 세포외 아세틸콜린 수준.
도 10b: 1-[2-(2,4-디메틸페닐술파닐)페닐]피페라진 HBr 염의 투여시 자유롭게 움직이는 래트에서의 배쪽 해마에서의 세포외 아세틸콜린 수준.
도 11: 습득 전 주어진 60 분에 Sprague-Dawley 래트에서 맥락 공포 조건화에 대한 1-[2-(2,4-디메틸페닐술파닐)페닐]피페라진 HBr 염의 유효성. 동결화 거동은 족부 쇼크 US (사전 쇼크 습득) 전의 58 초 동안의 습관화 기간 동안 스코어를 매겼다 (백색 바아). 동결화 거동은 트레이닝 24 시간 후에 측정했다 (기억력 시험) (흑색 바아).
도 12: 기억력 시험 전 주어진 1 시간에 Sprague-Dawley 래트에서의 맥락 공포 조건화에 대한 1-[2-(2,4-디메틸페닐술파닐)페닐]피페라진 HBr 염의 유효성. 동결화 거동은 족부 쇼크 US (사전 쇼크 습득) 전의 58 초 동안 스코어를 매겼다 (백색 바아). 동결화 거동은 트레이닝 24 시간 후에 측정했다 (기억력 시험).
도 13: 습득 후 즉시 주어진 때에 Sprague-Dawley 래트에서의 맥락 공포 조건화에 대한 1-[2-(2,4-디메틸페닐술파닐)페닐]피페라진 HBr 염의 유효성. 동결화 거동은 족부 쇼크 US (사전 쇼크 습득) 전의 58 초 동안 스코어를 매겼다 (백색 바아). 동결화 거동은 트레이닝 24 시간 후에 측정했다 (기억력 시험).
Claims (30)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200701607 | 2007-11-13 | ||
DKPA200701607 | 2007-11-13 | ||
DKPA200701788 | 2007-12-14 | ||
DKPA200701788 | 2007-12-14 | ||
DKPA200801300 | 2008-09-17 | ||
DKPA200801300 | 2008-09-17 | ||
PCT/DK2008/050271 WO2009062517A1 (en) | 2007-11-13 | 2008-11-12 | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity |
Publications (3)
Publication Number | Publication Date |
---|---|
KR20100099115A true KR20100099115A (ko) | 2010-09-10 |
KR101536023B1 KR101536023B1 (ko) | 2015-07-10 |
KR101536023B9 KR101536023B9 (ko) | 2023-03-29 |
Family
ID=40170671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107010492A KR101536023B1 (ko) | 2007-11-13 | 2008-11-12 | 조합된 sert, 5-ht3 및 5-ht1a 활성을 가진 화합물의 치료 용도 |
Country Status (30)
Country | Link |
---|---|
US (5) | US9278096B2 (ko) |
EP (3) | EP2431039B1 (ko) |
JP (2) | JP5603244B2 (ko) |
KR (1) | KR101536023B1 (ko) |
CN (1) | CN102014908A (ko) |
AR (1) | AR069260A1 (ko) |
AT (1) | ATE537829T1 (ko) |
AU (1) | AU2008323390B2 (ko) |
BR (1) | BRPI0820474B8 (ko) |
CA (1) | CA2705163C (ko) |
CL (1) | CL2008003363A1 (ko) |
CO (1) | CO6270322A2 (ko) |
CY (2) | CY1112646T1 (ko) |
DK (2) | DK2219647T4 (ko) |
EA (1) | EA027783B1 (ko) |
ES (2) | ES2379419T5 (ko) |
HR (2) | HRP20120144T4 (ko) |
HU (1) | HUE029588T2 (ko) |
IL (1) | IL205466A (ko) |
LT (1) | LT2431039T (ko) |
MX (1) | MX2010004688A (ko) |
NZ (1) | NZ585247A (ko) |
PL (2) | PL2431039T3 (ko) |
PT (2) | PT2219647E (ko) |
RS (2) | RS55147B1 (ko) |
SG (1) | SG10201405001XA (ko) |
SI (2) | SI2431039T1 (ko) |
TW (1) | TW200932233A (ko) |
WO (1) | WO2009062517A1 (ko) |
ZA (1) | ZA201003350B (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
EA021321B1 (ru) | 2009-08-24 | 2015-05-29 | Х. Лундбекк А/С | Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина |
TW201212918A (en) * | 2010-08-23 | 2012-04-01 | Lundbeck & Co As H | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
DK2667715T3 (en) * | 2011-01-27 | 2017-10-23 | Neuren Pharmaceuticals Ltd | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID |
WO2013012038A1 (ja) | 2011-07-21 | 2013-01-24 | 学校法人名城大学 | うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット |
NZ708595A (en) * | 2012-12-13 | 2019-06-28 | H Lundbeck As | Compositions comprising vortioxetine and donepezil |
JP6323979B2 (ja) * | 2013-01-17 | 2018-05-16 | 学校法人 名城大学 | うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット |
CN105339361A (zh) * | 2013-05-31 | 2016-02-17 | 斯洛文尼亚莱柯制药股份有限公司 | 用于合成1-(2-((2,4-二甲基苯基)硫代)苯基)哌嗪的新方法 |
EP2878596A1 (en) * | 2013-11-29 | 2015-06-03 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates |
EP3082815B1 (en) * | 2013-12-20 | 2018-10-03 | H. Lundbeck A/S | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
CN103788019B (zh) * | 2014-01-22 | 2015-10-07 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
US9822086B2 (en) | 2014-01-31 | 2017-11-21 | Egis Gyogyszergyar Zrt. | Process for the preparation of vortioxetine salts |
EP2930171A1 (en) * | 2014-04-07 | 2015-10-14 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate |
CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
CN108348486A (zh) * | 2015-07-17 | 2018-07-31 | 巴斯德研究院 | 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂 |
RU2018144248A (ru) | 2016-07-01 | 2020-08-03 | Х. Лундбекк А/С | Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта |
JP2023520016A (ja) | 2020-04-03 | 2023-05-15 | ハー・ルンドベック・アクチエゼルスカベット | 感情鈍麻の予防又は処置のための1-[2-(2,4-ジメチルフェニルスルファニル)-フェニル]ピペラジン |
WO2023036820A1 (en) | 2021-09-10 | 2023-03-16 | H. Lundbeck A/S | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
KR20230148676A (ko) | 2022-04-18 | 2023-10-25 | 영진약품 주식회사 | 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU163075A (en) * | 1975-07-21 | 1982-05-31 | Science Union & Cie | Process for preparing new phenoxy derivatives |
US5258387A (en) * | 1990-08-21 | 1993-11-02 | Hoffmann-La Roche Inc. | Tricyclic pyridone derivatives |
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
JP2005513128A (ja) * | 2001-12-20 | 2005-05-12 | ハー・ルンドベック・アクチエゼルスカベット | アリールオキシフェニル及びアリールスルファニルフェニル誘導体 |
SI1626720T1 (sl) | 2003-04-04 | 2008-12-31 | Lundbeck & Co As H | Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina |
US20060019938A1 (en) * | 2003-12-31 | 2006-01-26 | Beer Tomasz M | Estrogen administration for treating male cognitive dysfunction or improving male cognitive function |
BRPI0713425A2 (pt) * | 2006-06-16 | 2012-03-13 | H. Lundbeck A/S | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto |
TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
EA021321B1 (ru) | 2009-08-24 | 2015-05-29 | Х. Лундбекк А/С | Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина |
-
2008
- 2008-11-03 TW TW097142306A patent/TW200932233A/zh unknown
- 2008-11-11 AR ARP080104919A patent/AR069260A1/es unknown
- 2008-11-12 WO PCT/DK2008/050271 patent/WO2009062517A1/en active Application Filing
- 2008-11-12 ES ES08850935T patent/ES2379419T5/es active Active
- 2008-11-12 DK DK08850935.1T patent/DK2219647T4/da active
- 2008-11-12 LT LTEP11193237.2T patent/LT2431039T/lt unknown
- 2008-11-12 SI SI200831677A patent/SI2431039T1/sl unknown
- 2008-11-12 HU HUE11193237A patent/HUE029588T2/en unknown
- 2008-11-12 US US12/741,780 patent/US9278096B2/en active Active
- 2008-11-12 KR KR1020107010492A patent/KR101536023B1/ko active IP Right Review Request
- 2008-11-12 EA EA201070598A patent/EA027783B1/ru not_active IP Right Cessation
- 2008-11-12 BR BRPI0820474A patent/BRPI0820474B8/pt active IP Right Grant
- 2008-11-12 NZ NZ585247A patent/NZ585247A/en not_active IP Right Cessation
- 2008-11-12 MX MX2010004688A patent/MX2010004688A/es active IP Right Grant
- 2008-11-12 EP EP11193237.2A patent/EP2431039B1/en active Active
- 2008-11-12 JP JP2010533436A patent/JP5603244B2/ja active Active
- 2008-11-12 RS RS20160756A patent/RS55147B1/sr unknown
- 2008-11-12 SG SG10201405001XA patent/SG10201405001XA/en unknown
- 2008-11-12 SI SI200830548T patent/SI2219647T2/sl unknown
- 2008-11-12 CN CN2008801164637A patent/CN102014908A/zh active Pending
- 2008-11-12 EP EP16178423.6A patent/EP3115050A1/en not_active Withdrawn
- 2008-11-12 ES ES11193237.2T patent/ES2591110T3/es active Active
- 2008-11-12 RS RS20120087A patent/RS52256B2/sr unknown
- 2008-11-12 AT AT08850935T patent/ATE537829T1/de active
- 2008-11-12 EP EP08850935.1A patent/EP2219647B2/en active Active
- 2008-11-12 PT PT08850935T patent/PT2219647E/pt unknown
- 2008-11-12 CA CA2705163A patent/CA2705163C/en active Active
- 2008-11-12 PL PL11193237.2T patent/PL2431039T3/pl unknown
- 2008-11-12 PL PL08850935T patent/PL2219647T3/pl unknown
- 2008-11-12 CL CL2008003363A patent/CL2008003363A1/es unknown
- 2008-11-12 DK DK11193237.2T patent/DK2431039T3/en active
- 2008-11-12 PT PT111932372T patent/PT2431039T/pt unknown
- 2008-11-12 AU AU2008323390A patent/AU2008323390B2/en active Active
-
2010
- 2010-04-29 IL IL205466A patent/IL205466A/en active IP Right Grant
- 2010-05-12 ZA ZA2010/03350A patent/ZA201003350B/en unknown
- 2010-05-13 CO CO10057476A patent/CO6270322A2/es not_active Application Discontinuation
-
2012
- 2012-02-14 HR HRP20120144TT patent/HRP20120144T4/hr unknown
- 2012-02-24 CY CY20121100199T patent/CY1112646T1/el unknown
-
2014
- 2014-05-14 JP JP2014100815A patent/JP5841636B2/ja active Active
-
2016
- 2016-02-12 US US15/043,167 patent/US9744166B2/en active Active
- 2016-09-01 HR HRP20161121TT patent/HRP20161121T1/hr unknown
- 2016-09-07 CY CY20161100885T patent/CY1117978T1/el unknown
-
2017
- 2017-07-27 US US15/661,392 patent/US20180161321A1/en not_active Abandoned
-
2020
- 2020-05-12 US US15/930,014 patent/US11628166B2/en active Active
-
2023
- 2023-04-04 US US18/130,749 patent/US20240082239A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11628166B2 (en) | Therapeutic uses of compounds having combined sert, 5-HT3 and 5-HT1a activity | |
US8664225B2 (en) | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition | |
JP2013056933A (ja) | 認識機能障害(cognitiveimpairment)を治療するための、組み合わされたセロトニン再取り込み、5−HT3および5−HT1A活性を有する化合物としての1−[2−(2,4−ジメチルフェニルスルファニル)−フェニル]ピペラジン | |
AU2014200364B2 (en) | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20190617 Year of fee payment: 5 |
|
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2022100000852; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220325 Effective date: 20220811 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2022100000863; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220325 Effective date: 20221116 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2022100000847; TRIAL DECISION FOR INVALIDATION REQUESTED 20220324 Effective date: 20230113 Free format text: TRIAL NUMBER: 2022100000681; TRIAL DECISION FOR INVALIDATION REQUESTED 20220311 Effective date: 20230113 Free format text: TRIAL NUMBER: 2022100000680; TRIAL DECISION FOR INVALIDATION REQUESTED 20220311 Effective date: 20230113 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2022100000861; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220325 Effective date: 20230323 Free format text: TRIAL NUMBER: 2022100000860; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220325 Effective date: 20230323 |